Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term pramipexole for anhedonic depression (open-label follow-up)
2022-502270-17-00Phase 3Completed
- Sponsor
- Region Skåne
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pramipexole in major depressive disorder (MDD), sponsored by Region Skåne. Primary endpoint: Total SHAPS-C scores. Started Apr 2023; status: completed.
02
Drugs
pramipexole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-502270-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502270-17-00.